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Procalcitonin (PCT) is used as a biomarker in severe infections. Here, we retrospectively investigated levels of serum PCT,
C-reactive protein (CRP), and inflammatory cytokines (IL-6, TNF-α, and IFN-γ) in the second phase of patients with acute
encephalopathy with biphasic seizures and late reduced diffusion (AESD). Nine AESD pediatric patients (4 men, 5 women;
AESD group) admitted to Okayama University Hospital from 2010 to 2016 were compared with 10 control patients with
febrile seizures (FS) (3 men, 7 women; FS group). Mean PCT concentrations (ng/mL) in the AESD and FS groups were
significantly different, at 9.8± 6.7 and 0.8± 0.9, respectively (p = 0 0006). CRP (mg/dL) were 0.79± 0.89 and 1.4± 1.0 (p = 0 94),
respectively; IL-6 (pg/mL) were 449.7± 705.0 and 118.3± 145.4 (p = 0 20), respectively; TNF-α (pg/mL) were 18.6± 12.5 and
16.6± 6.0 (p = 0 67), respectively; and IFN-γ (pg/mL) were 79.6± 158.5 and 41.9± 63.7 (p = 0 56), respectively. Ratios of PCT to
CRP were 27.5± 34.2 and 3.2± 6.8 (p < 0 0001), respectively. The sensitivity and specificity in the diagnosis of AESD using a
cutoff of PCT/CRP ratio of 1.0 were 79% and 100%, respectively. These results suggest that PCT and the PCT/CRP ratio are
useful in auxiliary diagnosis of the second stage of AESD, and in AESD, PCT is likely to increase through a different mechanism.
1. Introduction
Procalcitonin (PCT) is a biomarker of systemic infection. It is
a more specific marker of microbial infections than C-
reactive protein (CRP) and is used in the diagnosis and
assessment of therapeutic effect in sepsis and other systemic
infections [1]. Acute encephalopathy (AE) is a severe compli-
cation causing brain dysfunction by a viral infection such as
influenza virus or human herpesvirus 6 (HHV-6). AE with
biphasic seizures and late reduced diffusion (AESD) is one
of the clinical subtypes of AE, which is characterized by a
febrile seizure (usually >30min) as the initial neurological
symptom, followed by secondary seizures at days 4 to 6 [2].
Here, we retrospectively investigated levels of serum PCT,
CRP, and inflammatory cytokines (IL-6, TNF-α, and IFN-γ)
in patients with AESD.
2. Materials and Methods
Nine AESD patients (4 men, 5 women; AESD group) admit-
ted to the Department of Pediatrics or the Department of
Emergency and Critical Care Medicine, Okayama University
Hospital, during the 7-year period from 2010 to 2016 were
compared with 10 control patients with complex febrile sei-
zures (3 men, 7 women; FS group). The AESD criteria used
were the characteristic clinical course which had secondary
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seizures within a week after febrile seizures, electroencepha-
logram (EEG) abnormalities characterized by generalized
high voltage slow waves and high signal foci in the subcorti-
cal white matter on diffusion-weighted head MR images
taken at the start of therapy or during follow-up. The criteria
of the FS group were status epilepticus lasting ≥15min plus a
clinical course eliminating the diagnosis of encephalopathy.
SerumPCT,CRP, and cytokinesweremeasured at the sec-
ond phase of AESD (before treatment) and onset of complex
febrile seizures. In AESD, the changes in PCT and CRP levels
during the follow-up period were measured. The measured
cytokines were IL-6, TNF-α, and IFN-γ, using aHumanCyto-
kine/Chemokine-Magnetic Bead Panel (Merck Millipore,
Germany) with a Luminex 100 system (Merck Millipore).
Statistical analysis was performed using Prism 6.0
software. Wilcoxon’s signed-rank test was used to evalu-
ate the statistical significance of differences between the two
groups (p < 0 05).
This study was approved by the Ethics Committee of the
Okayama University Graduate School of Medicine, Dentistry
and Pharmaceutical Sciences and Okayama University
Hospital (approval number: 1706-033).
3. Results
3.1. Patient Characteristics (Table 1). The average period
from the first seizure to the second seizure in the AESD group
was 5.3 days (range 4–7). Mean age at AESD onset was 13.9
(range 10–29) months, and pathogens of the preceding infec-
tion were influenza A virus (2 cases) and HHV-6 (7 cases).
All blood cultures were negative in the AESD group. Mean
age of FS onset was 26.6 (range 11–44) months, and causative
agents were HHV-6 (2 cases), adenovirus (1 case), human
metapneumovirus (1 case), hemolytic streptococcus (1 case),
and unknown (6 cases).
All patients were treated in accordance with the guide-
lines for the management of influenza-associated encepha-
lopathy from the time they were diagnosed as AESD. They
received pulse steroid therapy, immunoglobulin therapy,
mannitol, and edaravone, and five of them received targeted
temperature management [3].
3.2. PCT, CRP, and Cytokine Levels at the Start of Therapy
(Table 2).Mean PCT concentrations were significantly higher
in the AESD group than in the FS group (9.8± 6.7 ng/mL
and 0.8± 0.9 ng/mL, respectively; p = 0 0006), and 7 out of
9 patients had PCT levels exceeding the cutoff for severe
sepsis (2 ng/mL). Similarly, CRP concentrations were
0.79± 0.89mg/dL and 1.4± 1.0mg/dL (p = 0 94), respectively;
mean IL-6 concentrations were 449.7± 705.0 pg/mL and
118.3± 145.4 pg/mL (p = 0 20), respectively; TNF-α concen-
trations were 18.6±12.5pg/mL and 16.6±6.0pg/mL (p = 0 67),
respectively; and IFN-γ concentrations were 79.6±158.5pg/mL
and 41.9± 63.7 pg/mL (p = 0 56), respectively.
Elevation of CRP was less prominent compared with that
of PCT in AESD, resulting in a significantly higher PCT/CRP
ratio in the AESD group (27.5± 34.2) than in the FS group
(3.2± 6.8) (p < 0 0001). CRP levels often increase with eleva-
tion of PCT levels in sepsis [4, 5]. Figure 1 shows a
comparison of PCT/CRP ratios in patients with AESD and
in those with other diseases reported in this study or a previ-
ous study [4]. Ratios of all other diseases were lower than 1.0.
All patients had a PCT/CRP ratio > 1.0 in the AESD group,
compared with only 3 out of 10 in the FS group (Figure 2).
The diagnosis of AESD using a cutoff of a PCT/CRP ratio
of 1.0 gave a sensitivity of 79% and a specificity of 100%.
3.3. Time-Course Changes in PCT and CRP Levels (Figure 3).
PCT and CRP levels were measured on consecutive days dur-
ing follow-up in 5 AESD patients. In this figure, the day of the
secondary seizure is defined as day 0. PCT peaked in the very
early stage of therapy (0-1 days after the start of therapy);
however, the peak of CRP was delayed (0–3 days after the
start of therapy).
4. Discussion
There are three main categories in AE. The first group typi-
cally presents with cytokine storm and cerebral edema, the
second with AE with status epilepticus, and the third with
AE caused by metabolic derangement. The second group
AESD has become the most common (29%) in recent years
[6]. The pathogenic mechanism is hypothesized excitotoxic
injury with delayed neuronal death [2]. Although the fatality
is low (1.4%), AESD is difficult to diagnose, particularly in the
Table 1
AESD group (n = 9) FS group (n = 10)
Age, months 13.9 (10–29) 26.6 (11–44)
Sex (M/F), n 4/5 3/7
Pathogens∗, n
HHV-6: 7
Influenza: 2
HHV-6: 2
Adenovirus: 1
hMPV: 1
Hemolytic streptococcus: 1
Unknown: 6
Sequelae, n
None: 5
Mild: 2
Severe: 2
None: 10
AESD: acute encephalopathy with biphasic seizures and late reduced
diffusion; FS: febrile seizures; HHV-6: human herpesvirus-6; hMPV:
human metapneumovirus. ∗All AESD specimens were subjected to blood
culture, and the results were all negative.
Table 2
AESD group FS group p value
PCT (ng/mL) 9.8± 6.7 0.8± 0.9 0.0011
CRP (mg/dL) 0.79± 0.89 1.4± 1.0 0.21
PCT/CRP∗ 27.5± 34.2 3.2± 6.8 <0.0001
IL-6 (pg/mL) 449.7± 705.0 118.3± 145.4 0.20
TNF-α (pg/mL) 18.6± 12.5 16.6± 6.0 0.67
IFN-γ (pg/mL) 79.6± 158.5 41.9± 63.7 0.56
AESD: acute encephalopathy with biphasic seizures and late reduced
diffusion; CRP: C-reactive protein; FS: febrile seizures; PCT: procalcitonin.
Data are presented as the mean ± standard deviation. ∗The ratio was
calculated using a CRP value of 0.15 when it is below 0.15.
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early stage, and sequelae occur in a substantial proportion of
AESD patients (66.2%) [6]. Thus, identifying markers for
early diagnosis and developing effective therapies for AESD
is eagerly awaited [7].
PCT is a 13 kDa protein usually produced in the thyroid
as a precursor of calcitonin, a hormone involved in calcium
metabolism. However, in severe infections, it is produced in
the lungs and liver upon induction by endotoxins, IL-6,
and/or TNF-α. IFN-γ inhibits the synthesis of TNF-α,
thereby suppressing PCT production. Generally, sepsis and
severe sepsis are suspected when serum PCT levels exceed
0.5 and 2.0 ng/mL, respectively [8]. However, it increases in
systemic fungal infections, acute respiratory distress syn-
drome, acute pancreatitis, and Kawasaki disease, and thus,
PCT levels need to be judged carefully [9].
In the present study, we found several AESD patients
with significant increase of PCT in the second phase. In
reports on the relationship between AE and PCT, Takasu
et al. report that in a retrospective study of 7 cases of AESD
and 8 cases of febrile status epilepticus, PCT on the first
day was significantly higher in the AESD group [10], and
Azuma et al. report that in a retrospective study of 7 cases
of AESD, mean PCT concentrations were 16.2 pg/mL and 3
cases had PCT rising before MRI finding [11].
The present retrospective study comparing PCT levels
between the AESD and FS groups revealed that PCT was sig-
nificantly elevated in the second phase of AESD. Also, eleva-
tion of CRP was less prominent compared with that of PCT
in AESD, resulting in a significantly higher PCT/CRP ratio
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Figure 1: AESD: acute encephalopathy with biphasic seizures and late reduced diffusion; CRP: C-reactive protein; FS: febrile seizures; PCT:
procalcitonin; SIRS: systemic inflammatory response syndrome. PCT/CRP ratio = PCT average level (ng/mL)/CRP average level (mg/dL).
Data for the FS and AESD groups are from this study; other data is from Nakanishi et al. [4].
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Figure 2: AESD: acute encephalopathy with biphasic seizures and
late reduced diffusion; CRP: C-reactive protein; FS: febrile seizures;
PCT: procalcitonin. PCT/CRP ratio = PCT level (ng/mL)/CRP
level (mg/dL).
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Figure 3: CRP: C-reactive protein; mPSL pulse: methyl
prednisolone pulse therapy; PCT: procalcitonin. Follow-up after
diagnosis of acute encephalopathy with biphasic seizures and late
reduced diffusion and start of intervention. The day of secondary
seizure is defined as day 0. Data are presented as the mean
± standard deviation.
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in the AESD group than in the FS group. Discrepancies in
concentration changes between PCT and CRP may be
explained by (1) differences in cytokine kinetics and (2) dif-
ferences in PCT-producing cells and in production mecha-
nisms. Inflammatory cytokines such as IL-6 and TNF-α are
involved in the pathology of encephalopathy characterized
by cytokine storm. In AESD, levels of inflammatory cyto-
kines are increased in the cerebrospinal fluid but only slightly
in blood [12]. The present study did not find significant dif-
ferences in levels of cytokines involved in PCT production,
such as serum IL-6, TNF-α, and IFN-γ, between the AESD
and FS groups, suggesting that their effects are negligible. In
AESD, PCT is likely to increase through a different mecha-
nism from that obtained in sepsis, such as via the involve-
ment of distinct PCT-producing cells.
PCT level and PCT/CRP ratio appear to be useful
markers in the diagnosis of AESD: patients with a PCT/
CRP ratio > 1.0 are likely to have developed AESD. Future
studies with more cases will help further elucidate its clinical
significance and response mechanisms, which presently
remain unclear. AESD is difficult to diagnose in the early
stage, and brain dysfunction has often already occurred when
the disease is diagnosed.
The measurement of PCT and PCT/CRP ratio are safer
and easier than MRI or EEG for children, and they may lead
to auxiliary diagnosis of AESD. If we can prove that PCT will
rise before the second seizure attack, we can anticipate the
onset of AESD and intervene at an early stage.
5. Conclusion
This study investigated PCT and CRP levels in the second
stage of AESD. PCT level increased significantly, while CRP
level did not increase in comparison. Furthermore, PCT/
CRP ratio was extremely high in AESD compared with other
conditions. There were no significant differences in levels of
cytokines involved in PCT production, such as serum IL-6,
TNF-α, and IFN-γ, between the AESD and FS groups. In
AESD, PCT is likely to increase through a different mecha-
nism from that obtained in sepsis.
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